Key Services

We are committed to launching products that make a difference in people’s lives. We work across a product’s lifecycle, supporting biotech, pharmaceutical, and medical technology companies across the globe.

Outcomes Research

Our team provide unequalled accuracy and quality whilst delivering all aspects of systematic reviews, meta-analyses and patient-level data analyses.

Economic Modelling

We develop a range of robust health economic models that meet the commercial needs of our clients from simple Markov models to complex discrete event simulations.

Health Technology Assessment

We have extensive experience delivering successful HTA submissions in the UK and across the globe.

Value Communication

We effectively communicate the value of your products in a logical and insightful manner; from internal value dossiers to external scientific publications.

Pricing & Reimbursement

We partner with our clients to develop strategies for global pricing and reimbursement, harnessing our extensive KOL and payer network.


Mark Fisher, our Managing Director, participated and gave evidence in the Access to Medicines and Medical Devices All-Party Parliamentary Group (APPG) NICE Methods Review inquiry at the House of Commons in May. The APPG report has now been published which provides clear recommendations and suggestions for crucial areas for future research and work outside of the NICE review.

Contact Mark for more information about how this may impact your products, and how FIECON can help you navigate the best path for you going forward.




FIECON will be at ISPOR in Copenhagen in November and on-hand to discuss the latest thinking on how to bring products to market and what we can do to help our clients. Please contact our Commercial Director, if you would like to arrange a CEModelBuilder demo, to hear about our new product or to talk about how FIECON can support you.


Mark Fisher, our Managing Director, was speaking at the House of Commons alongside Sir Andrew Dillon (NICE), Helen Knight (NICE), and Karl Claxton (University of York) as part of the APPG inquiry into the NICE STA and HST methods. For full notes please email - key topics of discussion surrounded how NICE processes can look to close the gap between appraisals for rare and ultra-rare medicines, the role of NICE and NHS England in the assessment of budget impact, whether wider societal costs should be considered for the future, and much more.


Building cost-effectiveness models which can successfully demonstrate product value, can be time consuming and at the mercy of the developer.
Poorly designed models and human error can adversely affect commercial strategy. 
Can you afford to make these mistakes?
FIECON can help you build best-in-class cost-effectiveness models whilst significantly reducing building time. We have built a platform which automates the design and building-process of Excel-based cost-effectiveness models.
FIECON Model Builder can help you reduce the risk of human error and build high quality models in a matter of minutes rather than weeks. Our intuitive online interface leads to the quick and easy generation of customised models.
Give yourself the best chance of success; save time and money with the right cost-effectiveness model from FIECON Model Builder. Get in touch with our Managing Director,, to book a demo or find out more.